Literature DB >> 21576323

Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance.

Jessica M Breslow1, Joseph J Meissler, Rebecca R Hartzell, Phillip B Spence, Allan Truant, John Gaughan, Toby K Eisenstein.   

Abstract

Acinetobacter baumannii is a nosocomial pathogen with a high prevalence of multiple-drug-resistant strains, causing pneumonia and sepsis. The current studies further develop a systemic mouse model of this infection and characterize selected innate immune responses to the organism. Five clinical isolates, with various degrees of antibiotic resistance, were assessed for virulence in two mouse strains, and between male and female mice, using intraperitoneal infection. A nearly 1,000-fold difference in virulence was found between bacterial strains, but no significant differences between sexes or mouse strains were observed. It was found that microbes disseminated rapidly from the peritoneal cavity to the lung and spleen, where they replicated. A persistent septic state was observed. The infection progressed rapidly, with mortality between 36 and 48 h. Depletion of neutrophils with antibody to Ly-6G decreased mean time to death and increased mortality. Interleukin-17 (IL-17) promotes the response of neutrophils by inducing production of the chemokine keratinocyte-derived chemoattractant (KC/CXCL1), the mouse homolog of human IL-8. Acinetobacter infection resulted in biphasic increases in both IL-17 and KC/CXCL1. Depletion of neither IL-17 nor KC/CXCL1, using specific antibodies, resulted in a difference in bacterial burdens in organs of infected mice at 10 h postinfection. Comparison of bacterial burdens between IL-17a(-/-) and wild-type mice confirmed that the absence of this cytokine did not sensitize mice to Acinetobacter infection. These studies definitely demonstrate the importance of neutrophils in resistance to systemic Acinetobacter infection. However, neither IL-17 nor KC/CXCL1 alone is required for effective host defense to systemic infection with this organism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576323      PMCID: PMC3147579          DOI: 10.1128/IAI.00069-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.

Authors:  M L Joly-Guillou; M Wolff; R Farinotti; A Bryskier; C Carbon
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

2.  Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Authors:  Kyle I Happel; Mingquan Zheng; Erana Young; Lee J Quinton; Euan Lockhart; Alistair J Ramsay; Judd E Shellito; Jill R Schurr; Gregory J Bagby; Steve Nelson; Jay K Kolls
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

3.  Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.

Authors:  M J Rodríguez-Hernández; J Pachón; C Pichardo; L Cuberos; J Ibáñez-Martínez; A García-Curiel; F J Caballero; I Moreno; M E Jiménez-Mejías
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

4.  Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia.

Authors:  Marc J Schultz; Anita W Rijneveld; Sandrine Florquin; Carl K Edwards; Charles A Dinarello; Tom van der Poll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-02       Impact factor: 5.464

5.  Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.

Authors:  A Montero; J Ariza; X Corbella; A Doménech; C Cabellos; J Ayats; F Tubau; C Ardanuy; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Interleukin-17 and lung host defense against Klebsiella pneumoniae infection.

Authors:  P Ye; P B Garvey; P Zhang; S Nelson; G Bagby; W R Summer; P Schwarzenberger; J E Shellito; J K Kolls
Journal:  Am J Respir Cell Mol Biol       Date:  2001-09       Impact factor: 6.914

7.  Susceptibility to experimental Lyme arthritis correlates with KC and monocyte chemoattractant protein-1 production in joints and requires neutrophil recruitment via CXCR2.

Authors:  Charles R Brown; Victoria A Blaho; Christie M Loiacono
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

8.  In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain.

Authors:  Wen-Chien Ko; Hsin-Chun Lee; Shyh-Ren Chiang; Jing-Jou Yan; Jiunn-Jong Wu; Chin-Li Lu; Yin-Ching Chuang
Journal:  J Antimicrob Chemother       Date:  2004-01-16       Impact factor: 5.790

9.  Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses.

Authors:  Susumu Nakae; Yutaka Komiyama; Aya Nambu; Katsuko Sudo; Michiko Iwase; Ikuo Homma; Kenji Sekikawa; Masahide Asano; Yoichiro Iwakura
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

10.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  52 in total

1.  Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection.

Authors:  Brittany L Mortensen; Eric P Skaar
Journal:  Cell Microbiol       Date:  2012-06-14       Impact factor: 3.715

2.  NLRP3 inflammasome pathway has a critical role in the host immunity against clinically relevant Acinetobacter baumannii pulmonary infection.

Authors:  N Dikshit; S D Kale; H J Khameneh; V Balamuralidhar; C Y Tang; P Kumar; T P Lim; T T Tan; A L Kwa; A Mortellaro; B Sukumaran
Journal:  Mucosal Immunol       Date:  2017-06-14       Impact factor: 7.313

Review 3.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Authors:  R Parra Millán; M E Jiménez Mejías; V Sánchez Encinales; R Ayerbe Algaba; A Gutiérrez Valencia; M E Pachón Ibáñez; C Díaz; J Pérez Del Palacio; L F López Cortés; J Pachón; Y Smani
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Morphine, but not trauma, sensitizes to systemic Acinetobacter baumannii infection.

Authors:  Jessica M Breslow; M Alexandra Monroy; John M Daly; Joseph J Meissler; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 7.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

8.  Depletion of Alveolar Macrophages Increases Pulmonary Neutrophil Infiltration, Tissue Damage, and Sepsis in a Murine Model of Acinetobacter baumannii Pneumonia.

Authors:  Hiu Ham Lee; Lilit Aslanyan; Arjun Vidyasagar; Melissa B Brennan; Maxine S Tauber; Maria A Carrillo-Sepulveda; Michael R Dores; Nathan W Rigel; Luis R Martinez
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

9.  Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection.

Authors:  M Indriati Hood; Roman Uzhachenko; Kelli Boyd; Eric P Skaar; Alla V Ivanova
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

10.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.